PMID- 23132554
OWN - NLM
STAT- MEDLINE
DCOM- 20130116
LR  - 20221207
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 92
IP  - 6
DP  - 2012 Dec
TI  - HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a 
      systematic review.
PG  - 757-65
LID - 10.1038/clpt.2012.189 [doi]
AB  - Carbamazepine (CBZ) therapy is associated with cutaneous adverse reactions in up 
      to 10% of patients. Predisposition to these hypersensitivity reactions has been 
      linked to the human leukocyte antigen (HLA) genotype. This systematic review 
      determines the strength of these associations and accuracy of proposed genetic 
      screening. We determined that carriage of HLA-B*1502 in Asian patients was 
      associated with a pooled odds ratio (OR) of 113.4 (95% confidence interval (CI) = 
      51.2-251.0, P < 1 x 10(-5)) for CBZ-induced Stevens-Johnson syndrome (SJS) and 
      toxic epidermal necrolysis (TEN). A total of 461 patients would need to be 
      screened for HLA-B*1502 to prevent one episode of SJS/TEN. HLA-A*3101 is 
      significantly associated with all phenotypes of CBZ hypersensitivity in multiple 
      ethnicities with a pooled OR of 9.5 (95% CI = 6.4-13.9, P < 1 x 10(-5)). Between 
      47 and 67 patients would need to be tested for HLA-A*3101 to prevent one episode 
      of hypersensitivity. Our findings suggest that HLA testing before carbamazepine 
      therapy would be effective at identifying individuals at risk of hypersensitivity 
      and applicable to multiple populations providing hope for prevention in the 
      future.
FAU - Yip, V L
AU  - Yip VL
AD  - Department of Molecular and Clinical Pharmacology, University of Liverpool, 
      Liverpool, UK.
FAU - Marson, A G
AU  - Marson AG
FAU - Jorgensen, A L
AU  - Jorgensen AL
FAU - Pirmohamed, M
AU  - Pirmohamed M
FAU - Alfirevic, A
AU  - Alfirevic A
LA  - eng
GR  - G1000417/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20121107
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Anticonvulsants)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
CIN - Clin Pharmacol Ther. 2013 May;93(5):386-7. PMID: 23443751
CIN - Clin Pharmacol Ther. 2013 May;93(5):387. PMID: 23443755
MH  - Alleles
MH  - Anticonvulsants/*adverse effects
MH  - Asian People
MH  - Carbamazepine/*adverse effects
MH  - Case-Control Studies
MH  - Confidence Intervals
MH  - Drug Eruptions/*genetics
MH  - Drug Hypersensitivity/genetics
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/genetics
MH  - Humans
MH  - Odds Ratio
MH  - Predictive Value of Tests
EDAT- 2012/11/08 06:00
MHDA- 2013/01/17 06:00
CRDT- 2012/11/08 06:00
PHST- 2012/11/08 06:00 [entrez]
PHST- 2012/11/08 06:00 [pubmed]
PHST- 2013/01/17 06:00 [medline]
AID - clpt2012189 [pii]
AID - 10.1038/clpt.2012.189 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2012 Dec;92(6):757-65. doi: 10.1038/clpt.2012.189. Epub 2012 
      Nov 7.